![1]()
News
Apixaban noninferior to low-molecular-weight heparin in cancer-associated VTE
December 6, 2021
Is oral apixaban as safe and effective as subcutaneous dalteparin in treating venous thromboembolism (VTE) in patients with underlying cancer?
![1]()
News
Antibiotics vs. placebo in acute uncomplicated diverticulitis
December 3, 2021
Does antibiotic therapy decrease length of hospital stay for patients with acute uncomplicated diverticulitis?
News
Hospitals refused to give patients ivermectin. Lockdowns and political pressure followed.
December 3, 2021
“My patient was struggling to breathe, but the family refused to allow me to provide care. A call to the police was the only solution.”
![1]()
News
No serious CV risks for elderly after Pfizer COVID-19 vaccine
December 2, 2021
A French study adds to other evidence that the Pfizer mRNA COVID-19 vaccine does not increase the risk for serious cardiovascular adverse events in elderly individuals.
News
COVID-19 antibody drug likely works against Omicron, companies say
December 2, 2021
The preliminary findings haven’t yet been peer-reviewed.
News
Rituximab likely raises risk of hospital death in COVID-19 patients
December 2, 2021
In a retrospective study of hospitalized COVID-19 patients, “only 1 of 303 drugs examined, rituximab, was associated with an increased risk of in-hospital death ... both when used for rheumatologic as well as for cancer therapy.”
News
EXPLAINER-Does omicron pose higher risks for infants than other variants?
December 2, 2021
Asked whether people should be alarmed by the infant admissions numbers, Professor Anne von Gottberg told Reuters: “Not yet.”
![1]()
News
Tranexamic acid does not reduce risk of death in GI bleed
December 2, 2021
In patients with GI bleeding, does high-dose tranexamic acid (TXA) reduce the risk of death?
News
Second U.S. COVID-19 case caused by Omicron found
December 2, 2021
“This news is concerning, but it is not a surprise.”
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
